Digital Insomnia Therapeutics Market Report 2025

This Digital Insomnia Therapeutics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The digital insomnia therapeutics market size has grown strongly in recent years. It will grow from $3.27 billion in 2024 to $3.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.64%. The growth in the historic period of digital insomnia therapeutics can be attributed to an increased focus on sleep disorder education, growth in cross-platform compatibility, rise in eco-friendly devices, development of sustainable digital therapeutic options, and a greater emphasis on mental health.

The digital insomnia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.38%. The growth in the forecast period can be attributed to the adoption of virtual reality for sleep therapy, the emphasis on user-friendly interfaces, increased investment in sleep research, the expansion of voice-assisted sleep therapeutics, and the adoption of hybrid sleep treatment models. Major trends in the forecast period include technological advancements in digital health, integration of cognitive behavioral therapy (CBT-I), the use of AI and machine learning for treatment optimization, integration with other health apps, and the development of multilingual platforms to cater to a global audience.

The increasing adoption of digital health is expected to propel the digital insomnia therapeutics market in the coming years. Digital health involves the use of digital tools and platforms to improve healthcare delivery and patient outcomes. This trend is growing due to factors such as a rising demand for cost-effective and accessible healthcare, increasing prevalence of chronic diseases, awareness of preventive care, and the expansion of telehealth services. Digital insomnia therapeutics contribute to this trend by offering mobile apps, wearable devices, and other digital solutions that monitor, diagnose, and manage sleep disorders, improving overall health outcomes and integration with broader healthcare systems. For example, a survey by Rock Health in February 2024 revealed that 80% of respondents had used telemedicine at some point, an increase of 8 percentage points from 72% in 2021. This rise in the adoption of digital health is fueling the growth of the digital insomnia therapeutics market.

Companies in the digital insomnia therapeutics market are focusing on developing advanced, software-based mobile apps to provide personalized, accessible, and cost-effective treatment for insomnia. These apps feature functionalities such as sleep tracking, relaxation exercises, cognitive behavioral therapy, and personalized sleep recommendations. A key development came in August 2024 when Big Health Inc., a US-based mental health services company, announced that SleepioRx, a software-based app, had received approval from the United States Food and Drug Administration (FDA). SleepioRx is designed to treat chronic insomnia as an adjunct to standard care, targeting the cognitive and behavioral factors that contribute to sleep problems in adults.

In August 2022, ResMed Inc., a US-based medical device company, acquired Mementor for an undisclosed amount. The acquisition strengthens ResMed’s portfolio in digital health by integrating Mementor's advanced insomnia management solution, Somnio, into its offerings. Somnio is a digital health solution designed to improve sleep disorder treatment with evidence-based therapeutics. This acquisition aligns with ResMed's strategy to enhance patient care through innovative digital therapeutics in the sleep medicine space. Mementor is a Germany-based software company specializing in developing Somnio for digital insomnia management.

Major players in the digital insomnia therapeutics market are Pear Therapeutics Inc., Zuellig Pharma Holdings Limited, Calm.com Inc., Headspace Inc., Big Health Inc., Click Therapeutics Inc., Silvercloud Health Limited, Nox Health Group Inc., OPTT Inc., Curve Health Inc., Bodymatter Inc., Sana Health Group, SleepCogni Limited, Stellar Sleep, Somnus Therapeutics Inc., SleepScore Labs, HoneyNaps USA Inc., Sliiip, Neurovalens Ltd., WELT Corp.

North America was the largest region in the digital insomnia therapeutics market in 2024. The regions covered in digital insomnia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the digital insomnia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Digital insomnia therapeutics refer to technology-based solutions designed to treat or manage insomnia by improving sleep quality and addressing its root causes. These therapies utilize tools such as mobile apps, wearable devices, and online platforms to provide evidence-backed interventions. One common approach is cognitive behavioral therapy for insomnia (CBT-I), which targets the negative thoughts and behaviors that impact sleep.

The main types of digital insomnia therapeutics include sleep tracking apps, relaxation and meditation apps, CBT-I, wearable devices, and others. Sleep tracking apps monitor and analyze sleep patterns, offering actionable insights and recommendations to enhance sleep quality and address potential problems. These therapeutics are distributed through various channels, including hospital pharmacies, retail pharmacies, and other outlets, and are used across both medical and household applications.

The digital insomnia therapeutics market research report is one of a series of new reports that provides digital insomnia therapeutics market statistics, including the digital insomnia therapeutics industry global market size, regional shares, competitors with the digital insomnia therapeutics market share, detailed digital insomnia therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the digital insomnia therapeutics industry. This digital insomnia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The digital insomnia therapeutics market includes revenues earned by entities by providing services such as cognitive behavioral therapy for insomnia (CBT-I), sleep monitoring, relaxation techniques, and telehealth consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The digital insomnia therapeutics market consists of sales of virtual cognitive behavioral therapy, audio & video-based sleep aids, light and sound therapy devices, and sleep monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.